Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy-Reference-Cited by-同舟云学术

Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy

Published:2019-07-02 Issue:8 Volume:29 Page:609-627
ISSN:1001-0602
Container-title:Cell Research
language:en
Short-container-title:Cell Res

Author:

Zhang Yan,Du Xuexiang,Liu Mingyue,Tang Fei,Zhang Peng,Ai Chunxia,Fields James K.,Sundberg Eric J.,Latinovic Olga S.,Devenport Martin,Zheng Pan,Liu Yang

Funder

U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology

Link

http://www.nature.com/articles/s41422-019-0184-1.pdf

Reference49 articles.

1. Linsley, P. S. et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174, 561–569 (1991).

2. Freeman, G. J. et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation [see comments]. Science 262, 909–911 (1993).

3. Wu, Y., Guo, Y. & Liu, Y. A major costimulatory molecule on antigen-presenting cells, CTLA4 ligand A, is distinct from B7. J. Exp. Med. 178, 1789–1793 (1993).

4. Wing, K. et al. CTLA-4 control over Foxp3+regulatory T cell function. Science (New York, N.Y.) 322, 271–275 (2008).

5. Kuehn, H. S. et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science 345, 1623–1627 (2014).

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epigenetic-modifying agents: the potential game changers in the treatment of hematologic malignancies;Critical Reviews in Oncology/Hematology;2024-09

2. Toxicity in the era of immune checkpoint inhibitor therapy;Frontiers in Immunology;2024-08-23

3. Rational design of environmentally responsive antibodies with pH-sensing synthetic amino acids;Scientific Reports;2024-08-21

4. Molecular characteristics and immune microenvironment of gastrointestinal stromal tumours: targets for therapeutic strategies;Frontiers in Oncology;2024-07-12

5. Targeting cytotoxic lymphocyte antigen 4 (CTLA-4) in breast cancer;European Journal of Medical Research;2024-07-02